Back to company

AdaptVac ApS: Financial statements 2020

CVR: 38732730

AdaptVac ApS (CVR 38732730) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 20,231,326 and a net result of DKK 15,460,206 compared with DKK -185,145 the year before. That is an increase of 1,327.6% compared with the year before. Equity amounted to DKK 15,338,579. The solvency ratio was 39.7%. The company had 3 employees in the financial year.

Gross Profit
20,231,326 kr.
Profit/Loss
15,460,206 kr.
Equity
15,338,579 kr.
Total Assets
38,629,652 kr.
Employees
3

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2020-20.2 mio.15.5 mio.15.3 mio.3
2019-1.4 mio.-185 t.-122 t.3
2018-432 t.334 t.64 t.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is AdaptVac ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2020

AdaptVac ApS: The 2019 annual report is outMay 29, 2020

AdaptVac ApS has published its annual report for 2019. Gross profit came to DKK 1,417,122, and the net result was DKK -185,145.

Willem Adriaan De Jongh leaves the board of AdaptVac ApSFeb 26, 2020

As of February 26, 2020, Willem Adriaan De Jongh has left the board of directors of AdaptVac ApS.

Allan Rosetzsky joins the board of AdaptVac ApSJan 6, 2020

As of January 6, 2020, Allan Rosetzsky has joined the board of directors of AdaptVac ApS.

Morten Agertoug Nielsen joins the board of AdaptVac ApSJan 6, 2020

As of January 6, 2020, Morten Agertoug Nielsen has joined the board of directors of AdaptVac ApS.

Steen Søren Klysner leaves the board of AdaptVac ApSJan 6, 2020

As of January 6, 2020, Steen Søren Klysner has left the board of directors of AdaptVac ApS.

Morten Agertoug Nielsen leaves the board of AdaptVac ApSJan 5, 2020

As of January 5, 2020, Morten Agertoug Nielsen has left the board of directors of AdaptVac ApS.

About AdaptVac ApS

AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.

Other financial years